Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: OSENI

« Back to Dashboard
Oseni is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug.

This drug has two hundred and twenty-seven patent family members in forty-three countries.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Summary for Tradename: OSENI

Patents:18
Applicants:1
NDAs:1
Suppliers / Packagers: see list24

Clinical Trials for: OSENI

The Practical Evidence of Antidiabetic Combination Therapy in Korea
Status: Recruiting Condition: Type 2 Diabetes Mellitus

Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
Status: Completed Condition: Type 2 Diabetes Mellitus

Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
Status: Completed Condition: Type 2 Diabetes Mellitus

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes Mellitus

Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
Status: Completed Condition: Diabetes Mellitus

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes Mellitus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-001Jan 25, 2013RXNo6,890,898<disabled> <disabled>
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-003Jan 25, 2013RXYes5,965,584<disabled>Y <disabled>
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-006Jan 25, 2013RXNo5,965,584<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OSENI

Country Document Number Publication Date
South Korea101071390Oct 07, 2011
Peru16632008Dec 25, 2008
Czech Republic292093Jul 16, 2003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc